Galenica Sustainability and Business Performance

About Galenica Market environment Business performance Governance Sustainability Outlook Performance overview Galenica Group Strong sales and EBIT growth Net sales (in million CHF) +5.5% 1'960 1'857 H1 2021 H1 2022 -1.4% Adjusted²) EBIT (in million CHF) ROS (in %) +4.2% 101.4 100.0 -0.5% 1'378 1'435 H1 2021 5.5% 5.1% +7.3% 76.2 75.8 987 H1 2022 8.3% 7.7% 919 -3.7% Galenica Group Products & Care Logistics & IT Galenica Group Products & Care 26.3 25.4 1.9% 1.8% Logistics & IT Growth without COVID-19 +8.7% +11.8% +7.1% +19.8% +20.9% +15.6% initiatives 1) Net EBIT impact COVID-19 initiatives 1) 1 2 Impact of COVID-19 initiatives includes net sales of PCR tests, Rapid Antigen tests, self-tests as well as vaccinations, EBIT impact estimated Excluding effects of IAS 19 and IFRS 16, see chapter "Alternative performance measures" of the Half-year Report 2022 08/08/22 44 -17 million CHF -13 million CHF -4 million CHF GALENICA

View entire presentation